Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia.
10.3904/kjim.2010.25.1.27
- Author:
Jong Seon PARK
1
;
Young Jo KIM
;
Ji Yong CHOI
;
Yoon Nyun KIM
;
Teck Jong HONG
;
Dong Soo KIM
;
Ki Young KIM
;
Myung Ho JEONG
;
Jei Keon CHAE
;
Seok Kyu OH
;
In Whan SEONG
Author Information
1. Department of Internal Medicine, Yeungnam University Medical Cencer, Daegu, Korea. yjkim@med.yu.ac.kr
- Publication Type:Original Article ; Comparative Study ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Metabolic syndrome X;
Hypercholesterolemia;
Rosuvastatin;
Atorvastatin
- MeSH:
Blood Glucose/metabolism;
Cholesterol, LDL/blood;
Female;
Fluorobenzenes/*administration & dosage;
Hemoglobin A, Glycosylated/metabolism;
Heptanoic Acids/*administration & dosage;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage;
Hypercholesterolemia/blood/complications/*drug therapy;
Hyperglycemia/blood/complications/*drug therapy;
Insulin/blood;
Male;
Metabolic Syndrome X/blood/complications/*drug therapy;
Middle Aged;
Pyrimidines/*administration & dosage;
Pyrroles/*administration & dosage;
Sulfonamides/*administration & dosage;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2010;25(1):27-35
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: This multicenter, open-labeled, randomized trial was performed to compare the effects of rosuvastatin 10 mg and atorvastatin 10 mg on lipid and glycemic control in Korean patients with nondiabetic metabolic syndrome. METHODS: In total, 351 patients who met the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) levels > or = 130 mg/dL were randomized to receive either rosuvastatin 10 mg (n = 173) or atorvastatin 10 mg (n = 178) for over 6 weeks. RESULTS: After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 +/- 11.38 vs. - 30.07 +/- 10.46%, p < 0.001), LDL-C (48.04 +/- 14.45 vs. 39.52 +/- 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 +/- 13.15 vs. - 35.52 +/- 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 +/- 18.85 vs. - 32.57 +/- 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group. Overall, the percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin (87.64 vs. 69.88%, p < 0.001). Changes in glucose and insulin levels, and homeostasis model assessment of insulin resistance index were not significantly different between the two groups. The safety and tolerability of the two agents were similar. CONCLUSIONS: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals.
